Information Provided By: 
Fly News Breaks for February 24, 2017
MRK, ENDP, AVDL
Feb 24, 2017 | 07:15 EDT
SunTrust analyst John Boris reduced his price target on Avadel (AVDL) after Endo (ENDP) launched an injectable drug that will compete, at a similar price point, with Avadel's Akovaz. The analyst adds that Avadel's Bloxiverz is also being challenged by Merck's (MRK) Bridion which is taking share in the neostigmine market. He lowered his estimates for Avadel below consensus levels but keeps a Buy rating on the name.
News For AVDL;ENDP;MRK From the Last 2 Days
AVDL
Apr 17, 2024 | 08:01 EDT
Notable profits for the buyer who lifted the $3.50 offer for 1,657 Avadel Pharmaceuticals (AVDL) Jan-25 17.5 calls yesterday at 09:59ET when underlying shares were trading at $17.07. Shares closed at $18.09, and the calls at $4.10 for a mark-to-market profit of 17%, or $100K, on the $580K outlay.
